SEC Form 4 · accession 0000919574-19-000365

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Director · 10% Owner

Director · 10% Owner

Period of report

Jan 9, 2019

Accepted (ET)

Jan 11, 2019 · 6:04 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001534120

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jan 9, 2019	P	545	$3.788	A	18,156,348	I	See Footnote
Common Stock^F1	Jan 10, 2019	P	800	$3.698	A	18,157,148	I	See Footnote
Common Stock^F1	Jan 11, 2019	P	6,651	$3.9078	A	18,163,799	I	See Footnote
Common Stock^F1	Jan 11, 2019	P	2,500	$3.8872	A	18,166,299	I	See Footnote
Common Stock^F1	Jan 11, 2019	P	2,500	$3.878	A	18,168,799	I	See Footnote
Common Stock^F1	Jan 11, 2019	P	421	$3.8933	A	18,169,220	I	See Footnote
Common Stock^F1	Jan 11, 2019	P	579	$3.92	A	18,169,799	I	See Footnote

No Table II lines on this filing.

F1The reported securities are directly owned by certain investment advisory clients of Armistice Capital, LLC ("Armistice Capital"), and may be deemed to be indirectly beneficially owned by Armistice Capital as the investment manager of such advisory clients. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.